Solving the Capacity Crisis for Viral Vector Manufacturing

Solving the Capacity Crisis for Viral Vector Manufacturing

Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.

Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.

Participants will learn:

  1. The manufacturing challenges facing the viral vector industry
  2. The advantages of an integrated manufacturing solution
  3. How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom

 

 

 

Moderator

 

 

Charlotte Masy

Clive Glover

 

Director, Cell & Gene Therapy
Pall Biotech

 

 

 

Presenters

 

 

 

Charlotte Masy

Jeremy Rautenbach

 

Global Product Manager, Integrated Solutions
Pall Biotech

Charlotte Masy

Joseph Rininger

 

Director, Cell & Gene Therapy
Latham BioPharm Group

Charlotte Masy

Peter Makowensky

 

Director, Sales Engineering

G-CON Manufacturing

Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing

Listen to Podcast Today

더 Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
March 2021
Case Study: Swissfillon’s Approach to Single-Use Formulation & Filling

Biotech | Pall Corporation 웨비나 시리즈

In 2019 Swissfillon were inspected and approved by the FDA to supply drug products into the USA, following on from EU approval in 2018. This young fill finish CMO was started in Switzerland in 2013 and built a state-of-the-art cGMP production facility from the ground up.

Swissfillon recognized early on that single-use systems met their requirements for multi-product manufacturing and would help their clients get their drugs to market faster.

During this case-study webinar, participants will learn:

  1. How working in partnership with a supplier can be part of a QbD approach to minimize risk
  2. Strategies & design improvements for single-use systems to reduce risk in the process
  3. How a shadowboard can be used to make single-use system leak tests, PUPSIT and the filtration process fast, safe and simple
시청